For the second time this year, appellate lawyers at O’Melveny & Myers have wiped out a huge jury verdict against Johnson & Johnson Inc. and a subsidiary over their marketing of the antipsychotic drug Risperdal. The reversals are a blow to plaintiffs firm Bailey Peavy Bailey, which has now seen $250 million in attorney fee awards go up in smoke.
The Arkansas Supreme Court vacated on Thursday a $1.2 billion jury verdict that the Arkansas Attorney General’s Office won in a suit alleging that J&J and subsidiary Janssen Pharmaceuticals Inc. didn’t properly communicate Risperdal’s risks and illegally marketed it for off-label uses. The court also set aside a $181 million fee award for Bailey Peavy Bailey, which handled the case on the state’s behalf.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
